Mobile

A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmith...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-002680-18

A phase II, controlled, randomized, single blind study to evaluate the immunogenicity, safety and reactogenicity of the low dose influenza vaccine adjuvanted with AS03 compared to Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in elderly 60 years and older

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the humoral immune response (anti-haemagglutinin) elicited by the low dose influenza vaccine adjuvanted with AS03 and by Fluarix, with the Northern Hemisphere 2006-2007 influenza vaccine composition, 21 days after vaccination.

Critère d'inclusion

  • Immunization against influenza in male and female subjects aged 60 years and older

Liens